Detailansicht

Wissensnetz

Person

Dirk Hose (1969-)

Physiker

Name	Dirk Hose
Zeit	1969- (Lebensdaten)
Ort	Gießen (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr.
Beruf	Physiker (charakteristischer Beruf) Arzt
Variante	D. Hose
Beziehung	Medizinische Klinik und Poliklinik (Heidelberg, 5)
Weitere Angaben	Diss. Medizinische Fakultät an der Universität Heidelberg Leiter des Labors für Myelomforschung
Datensatztyp	Person
GND-Nummer	139824995
Datensatz-ID	139824995
Beteiligt an alle anzeigen Modelling myeloma dissemination in vitro with hMSC-interacting subpopulations of INA-6 cells and their aggregation/detachment dynamics Transcriptome Profiling Assessing Pathogenesis and Prognosis of Plasma Cell Dyscrasias - Bioinformatic Basis for Clinical Application Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival Molecular pathogenesis and progression of light chain amyloidosis Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions Asymptomatic multiple myeloma molecular background of progression, evolution, and prognosis SULFs in human neoplasia: implication as progression and prognosis factors Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays Aurora-Kinase-Inhibition zur personalisierten und risikoadaptierten Therapie des Multiplen Myeloms A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Dirk Hose (1969-)

Modelling myeloma dissemination in vitro with hMSC-interacting subpopulations of INA-6 cells and their aggregation/detachment dynamics

Transcriptome Profiling Assessing Pathogenesis and Prognosis of Plasma Cell Dyscrasias - Bioinformatic Basis for Clinical Application

Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival

Molecular pathogenesis and progression of light chain amyloidosis

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome

A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma

Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions

Asymptomatic multiple myeloma  molecular background of progression, evolution, and prognosis

SULFs in human neoplasia: implication as progression and prognosis factors

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

Aurora-Kinase-Inhibition zur personalisierten und risikoadaptierten Therapie des Multiplen Myeloms

A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

Asymptomatic multiple myeloma molecular background of progression, evolution, and prognosis